ABSTRACT
In the title compound, [Co(NO(3))(2)(C(18)H(16)N(2)O(2))(2)](n), the Co(II) ion is located on an inversion center and is six-coordinated in an octa-hedral environment defined by four N atoms of the pyridine rings and two O atoms of the nitrate anions. The ligands link the Co(II) ions into a linear chain running along [201]. One O atom of the nitrate ligand is disordered over two positions with site-occupancy factors of 0.59â (4) and 0.41â (4).
ABSTRACT
In the title compound, [HgCl(2)(C(18)H(16)N(2)O(2))](n), the Hg(II) atom is four-coordinated in a distorted tetra-hedral environment defined by two Cl atoms and two N atoms from two 1,4-bis-(pyridin-2-ylmeth-oxy)benzene ligands. The ligand shows a non-coplanar conformation, in which the dihedral angles between the two terminal pyridine rings and the linking benzene ring are 7.275â (17) and 74.020â (14)°. The flexible ligands link the Hg(II) atoms into a chain running along [010], with an Hgâ¯Hg separation of 10.335â (5)â Å, which is equal to the b axis. The chains are connected by C-Hâ¯O and C-Hâ¯Cl hydrogen bonds.
ABSTRACT
In the title compound, [ZnCl(2)(C(18)H(16)N(2)O(2))](n), the Zn(II) ion is tetra-hedrally coordinated by two Cl atoms and by two N atoms from different 1,4-bis-(pyridin-2-ylmeth-oxy)benzene ligands. The ligand shows a non-planar configuration, in which the dihedral angles between the two terminal pyridine rings and the linking benzene ring are 7.86â (12) and 70.74â (11)°. The flexible ligand coordinates to the Zn(II) ions, generating an infinite chain propagating along [001].
ABSTRACT
In the title compound, [Ag(C(12)H(11)NO(2))(2)]NO(3)·H(2)O, the Ag(I) ion is coordinated by two N atoms from two different 4-(4-pyridyl-meth-oxy)phenol ligands, generating a nearly linear coordination geometry with an N-Ag-N angle of 167.1â (1)°. A three-dimensional supra-molecular network is built from the uncoordinated nitrate anion, the water mol-ecule and the cation through O-Hâ¯O hydrogen bonds.
ABSTRACT
BACKGROUND: No specific antiviral agent against hand foot and mouth disease (HFMD) is available for clinical practice today. OBJECTIVE: To evaluate the efficacy and safety of Jinzhen oral solution in treating uncomplicated HFMD. METHODS: In this randomized, double-blind, placebo-controlled trial, 399 children aged 1 to 7 years with laboratory confirmed HFMD were randomized to receive Jinzhen oral liquid or placebo 3 times daily for 7 days with a 3-day follow-up. The primary outcomes were time to the first disappearance of oral ulcers and vesicles on hand or foot and time to the first normalization of temperature (fever clearance). RESULTS: There were 199 children enrolling into the Jinzhen group including 79 with fever and 200 into the placebo group including 93 with fever. Jinzhen reduced the time to the first disappearance of oral ulcers and vesicles on hand or foot to 4.9 days (95% CI, 4.6 to 5.2 days), compared with 5.7 days (95% CI, 5.4 to 6.0 days) in the placebo group (Pâ=â0.0036). The median time of fever clearance was shorter in the 79 children who received Jinzhen (43.41 hrs, 95% CI, 37.05 to 49.76) than that in the 93 children who received placebo (54.92 hrs, 95% CI, 48.16 to 61.68) (Pâ=â0.0161). Moreover, Jinzhen reduced the risk of symptoms by 28.5% compared with placebo (HR, 0.7150, 95% CI, 0.5719 to 0.8940, Pâ=â0.0032). More importantly, treatment failure rate was significantly lower in the Jinzhen group (8.04%) compared with that in the placebo group (15.00%) (Pâ=â0.0434). The incidence of serious adverse events did not differ significantly between the two groups (9 in Jinzhen group vs. 18 in placebo, Pâ=â0.075). CONCLUSIONS: Children with HFMD may benefit from Jinzhen oral liquid treatment as compared with placebo. TRIAL REGISTRATION: Chinese Clinical Trial Registry (http://www.chictr.org/en/) ChiCTR-TRC-10000937.